WallStSmart

Cytokinetics Inc (CYTK)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Cytokinetics Inc generates 14161% more annual revenue ($105.81M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. CYTK earns a higher WallStSmart Score of 32/100 (F).

CYTK

Avoid

32

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 4.0Quality: 6.5
Piotroski: 3/9Altman Z: -4.58

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CYTKSignificantly Overvalued (-27.5%)

Margin of Safety

-27.5%

Fair Value

$61.78

Current Price

$80.01

$18.23 premium

UndervaluedFair: $61.78Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CYTK2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
1126.0%10/10

Revenue surging 1126.0% year-over-year

Debt/EquityHealth
-1.5610/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.299/10

Conservative balance sheet, low leverage

Areas to Watch

CYTK4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-572.0%2/10

ROE of -572.0% — below average capital efficiency

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : CYTK

The strongest argument for CYTK centers on Revenue Growth, Debt/Equity. Revenue growth of 1126.0% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : CYTK

The primary concerns for CYTK are EPS Growth, Profit Margin, Piotroski F-Score.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

CYTK profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

CYTK is growing revenue faster at 1126.0% — sustainability is the question.

CYTK generates stronger free cash flow (-151M), providing more financial flexibility.

Bottom Line

CYTK scores higher overall (32/100 vs 24/100) and 1126.0% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cytokinetics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Cytokinetics, Incorporated, an advanced stage biopharmaceutical company, focuses on discovering, developing and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is headquartered in South San Francisco, California.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?